PetMed Express (NASDAQ:PETS) announced its quarterly earnings results on Monday. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.11, Bloomberg Earnings reports. PetMed Express had a net margin of 12.84% and a return on equity of 34.04%. The company had revenue of $60.10 million for the quarter, compared to the consensus estimate of $56.76 million. During the same quarter in the prior year, the firm earned $0.24 earnings per share. The company’s revenue for the quarter was up 13.6% compared to the same quarter last year.

PetMed Express (NASDAQ PETS) opened at $50.66 on Wednesday. The firm has a market cap of $991.27, a P/E ratio of 29.98, a PEG ratio of 2.83 and a beta of 1.12. PetMed Express has a 52-week low of $19.21 and a 52-week high of $57.80.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 16th. Stockholders of record on Monday, February 5th will be given a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.97%. The ex-dividend date of this dividend is Friday, February 2nd. This is a positive change from PetMed Express’s previous quarterly dividend of $0.20. PetMed Express’s payout ratio is currently 47.34%.

Several analysts have issued reports on the stock. BidaskClub downgraded shares of PetMed Express from a “strong-buy” rating to a “buy” rating in a report on Friday, January 19th. Northcoast Research set a $58.00 price target on shares of PetMed Express and gave the company a “buy” rating in a report on Wednesday, January 3rd. Noble Financial reaffirmed a “hold” rating on shares of PetMed Express in a report on Friday, October 27th. Zacks Investment Research raised shares of PetMed Express from a “sell” rating to a “hold” rating and set a $50.00 price target on the stock in a report on Friday, October 20th. Finally, ValuEngine lowered shares of PetMed Express from a “buy” rating to a “hold” rating in a research report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the stock. PetMed Express currently has an average rating of “Hold” and an average price target of $42.80.

In other news, Director Gian Fulgoni sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $44.38, for a total value of $887,600.00. Following the completion of the transaction, the director now owns 55,900 shares of the company’s stock, valued at $2,480,842. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Menderes Akdag sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $51.00, for a total transaction of $1,530,000.00. Following the transaction, the chief executive officer now directly owns 490,000 shares of the company’s stock, valued at approximately $24,990,000. The disclosure for this sale can be found here. In the last three months, insiders sold 51,000 shares of company stock valued at $2,453,170. Company insiders own 4.00% of the company’s stock.

A number of hedge funds have recently modified their holdings of PETS. Schwab Charles Investment Management Inc. increased its position in PetMed Express by 20.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 84,764 shares of the company’s stock worth $3,442,000 after purchasing an additional 14,456 shares during the last quarter. Legal & General Group Plc increased its position in PetMed Express by 9.0% during the second quarter. Legal & General Group Plc now owns 36,258 shares of the company’s stock worth $1,472,000 after purchasing an additional 2,992 shares during the last quarter. Principal Financial Group Inc. increased its position in PetMed Express by 4.0% during the second quarter. Principal Financial Group Inc. now owns 173,219 shares of the company’s stock worth $7,033,000 after purchasing an additional 6,741 shares during the last quarter. Alliancebernstein L.P. acquired a new position in PetMed Express during the second quarter worth approximately $2,212,000. Finally, Teachers Advisors LLC increased its position in PetMed Express by 5.3% during the second quarter. Teachers Advisors LLC now owns 65,173 shares of the company’s stock worth $2,646,000 after purchasing an additional 3,289 shares during the last quarter. 99.24% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “PetMed Express (PETS) Releases Quarterly Earnings Results” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://theolympiareport.com/2018/01/24/petmed-express-pets-releases-quarterly-earnings-results.html.

About PetMed Express

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Earnings History for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.